2. Dimke H., Hoenderop J.G. Molecular basisof epithelial Ca2+ and Mg2+ transport: insights from the TRP channel famile. J. Physiol. 2011;589 (pt 7):1535–1542.

3. Institute of Medicine, Food and Nutrition. Dietary reference intakes for Calcium and Vitamin D. Washington, DC. National Academy Press, 2010.

4. Guyton K.Z., Kenser T.W., Posner G.H. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr. Rev. 2003;61(7):227–238.

5. Davis C.D., Hartmuller V., Freedman M., Hartge P., Picciano M.F., Swanson C.A.,Milner J.A. Vitamin D and cancer: current dilemmas and future needs. Nutr Rev. 2007;65:S71–S74.

6. Davis C.D. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr. 2008;88:565S–9S.

7. Lips P., Duong T., Oleksik A., Black D., Cummings S., Cox D. et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab. 2001;86(3):1212–1222.

8. Ticinesi A., Nouvenne A., Ferraro P.M., et al. Idiopathic Calcium Nephrolithiasis and Hypovitaminosis D: a Case-Control Study. Urology. 2015.

9. Garland C.F., Comstock G.W., Garland F.C., Helsing K.J., Shaw E.K., Gorham E.D. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989;2(8673):1176–1178.

10. Ahonen M.H., Tenkanen L., Teppo L., Hakama M., Tuohimaa P. Prostate cancer risk and rediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 2000;11(9):847–852.

11. Zittermann A., Schleithoff S.S., Tenderich G., Berthold H.K., Korfer R., Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41(1):105–112.

12. Knekt P., Laaksonen M., Mattila C., Harkanen T., Marniemi J., Heliovaara M. et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology. 2008;19(5):666–671.

13. Pittas A.G., Dawson-Hughes B., Li T. et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006;29(3):650–56.

14. Afzal S., Brøndum-Jacobsen P., Bojesen S.E., Nordestgaard B.G. Vitamin D concentration, obesity, and risk of diabetes: a mendelianrandomisation study. Lancet Diabetes Endocrinol. 2014;2(4):298–306. [PubMed: 24703048

15. Schneider B., Weber B., Frensch A., Stein J., Fritz J. Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm. 2000;107(7):839–842.

16. Lauderdale D.S., Thisted R.A., Wen M., Favus M.J. Bone mineral density and fracture among prevalent kidney stone cases in the Third National Health and Nutrition Examination Survey. J Bone Miner Res. 2001;16(10):1893–1898.

17. Ferraro P.M., Taylor E.N., Eisner B.H., Gambaro G., Rimm E.B., Mukamal K.J.et al. History of kidney stones and the risk of coronary heart disease. JAMA 2013;310(4):408–415.

18. Nemere I., Leathers V., Norman A.W. 1,25-Dihydroxyvitamin D3-mediated intestinal calcium transport. Biochemical identification of lysosomes containing calcium and calcium-binding protein (calbindin-D28K). J Biol Chem. 1986; 261: 16106–1614.

19. Hoenderop J.G., Nilius B., Bindels R.J. Calcium absorption across epithelia. Physiol Rev. 2005; 85: 373–422.

20. Hawa N.S., O’Riordan J.L., Farrow S.M. Functional analysis of vitamin D response elements in the parathyroid hormone gene and a comparison with the osteocalcin gene. BiochemBiophys Res Commun. 1996;228:352–357.

21. Pearle M.S., Antonelli J.A., Lotan Y. Urinary lithiasis: Etiology, epidemiology, and pathogenesis. In Campbell-Walsh Urology, 11th ed.

22. Wein A.J., Kavoussi L.R., Partin A.W., Peters A.C., Eds.; Elsevier: Philadelphia, PA, USA. 2016;2:1170–1199.

23. Giannini S.N.M., Castrignano R., Pati T., Tasca A., Villi G., Pellegrini F., D’Angelo A. Possible link between vitamin D and hyperoxaluria in patients with renal stone disease. ClinSci (Lond) 1983;84:51–54.

24. Broadus A.E., Insogna K.L., Lang R., Ellison A.F., Dreyer B.E. Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med. 1984;311(2):73–80.

25. Shakhssalim N., Gilani K.R., Parvin M. et al. An assessment of parathyroid hormone, calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors. Urol Res. 2011; 39(1):1–7.

26. Gebhardt K. Iatrogenic kidney-calculi formation and kidney failure due to long-term treatment with calcinosis factors (dihydrotachysterol, vitamin D). Z ArztlFortbild (Jena) 1977; 71:447–449.

27. Worcester E.M., Coe F.L. Clinical practice. Calcium kidney stones. N Engl J Med. 2010;363:954–963.

28. Pak C.Y., Kaplan R., Bone H., Townsend J., Waters O. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med. 1975;292(10):497–500.

29. Robertson W.G., Peacock M., Nordin B. E. Calcium oxalate crystalluria and urine saturation in recurrent renal stone-formers. Clin. Sci.1971;40:365–374.

30. Shih E.V., Mahova A.A. The vitamins in clinical practice. Prakticheskaya medicina. M., 2014. P. 251–293. Russian (Ших Е.В., Махова А.А. Витамины в клинической практике. Практическая медицина. М., 2014. С. 251–293).

31. Holick M. The Vitamin D epidemic and its health consequences. Am Soc Nutrition. 2005;2739–2748.

32. Kim W.T., Kim Y.-J., Yun S.J. et al. Role of 1,25-Dihydroxy Vitamin D3 and Parathyroid Hormone in Urinary Calcium Excretion in Calcium Stone Formers. Yonsei Medical Journal. 2014;55(5):1326–1332. Doi:10.3349/ymj.2014.55.5.1326.

33. Hu H., Zhang J., Lu Y., Zhang Z. et al. Association between Circulating Vitamin D Level and Urolithiasis: A Systematic Review and Meta-Analysis. Nephrol Dial Transplant. 2012;27(12):4385–4389. doi: 10.1093/ndt/gfs297.

34. Hu H., Zhang J., Lu Y., Zhang Z. et al. Wang Association between Circulating Vitamin D Level and Urolithiasis: A Systematic Review and Meta-Analysis. *Nutrients. 2017;9:301. Doi:10.3390/nu9030301.

35. Gray R.W., Wilz D.R., Caldas A.E., Lemann J. Jr. The importance of phosphate in regulating plasma 1,25-(OH)2-vitamin D levels in humans: studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 1977;45(2):299–306.

36. Schlingmann K.P., Ruminska J., Kaufmann M. et al. Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia. Journal of the American Society of Nephrology : JASN. 2016;27(2):604–614. doi:10.1681/ASN.2014101025.

37. Schlingmann K.P., Kaufmann M., Weber S., Irwin A., Goos C., John U., Misselwitz J., Klaus G., Kuwertz-Bröking E., Fehrenbach H., Wingen A.M., Güran T., Hoenderop J.G., Bindels R.J., Prosser D.E., Jones G., Konrad M. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011;365(5):410–421. Doi: 10.1056/NEJMoa1103864.

38. Nesterova G., Malicdan M.C., Yasuda K. et al. 1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis. Clinical Journal of the American Society of Nephrology : CJASN. 2013;8(4):649–657. Doi:10.2215/CJN.05360512.

39. Friedman P.A. Calcium transport in the kidney. Current Opinion in Nephrology & Hypertension. 1999;8(5):589–595.

40. Iida K., Shinki T., Yamaguchi A., DeLuca H.F., Kurokawa K., Suda T. A possible role of vitamin D receptors in regulating vitamin D activation in the kidney. Proc Natl Acad Sci USA. 1995;92(13):6112–6116.

41. Khashayar Sakhaee, Naim M, Maalouf et al. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int 2011; 79 (4): 393–403. doi:10.1038/ki.2010.473.

42. Pigarova E.A., Mirnaya S.S., Belyaeva A.V. et al. The analysis of biochemical predictors of urinary stone disease in patients with primary hyperparathyreosis. Mat. Vseros. nauch.-prakt. konf. s megdunar. uch. “Almazovskye chteniya 2011”, posvyashchennoy 80-letiyu so dnya rojdenya akademika RAMN V.A. Almazova SPb., 2011. Russian (Пигарова E.A., Мирная С.С., Беляева А.В и др. Анализ биохимических предикторов нефролитиаза у пациентов с первичным гиперпаратиреозом. Мат. Всерос. науч.-практ. конф. c междунар. уч. «Алмазовские чтения 2011», посвященной 80-летию со дня рождения академика РАМНВ.А. Алмазова. СПб., 2011).

43. Tang J., Chonchol M.B. Vitamin D and kidney stone disease. Curr Opin Nephrol Hypertens. 2013;22(4):383–89. doi: 10.1097/MNH.0b013e328360bbcd.

44. Nguyen S., Baggerly L., French C., Heaney R.P., Gorham E.D., Garland C.F.25-Hydroxyvitamin D in the range of 20 to 100 ng/mL and incidence of kidney stones. Am J Public Health. 2014;104(9):1783–87. doi: 10.2105/AJPH.2013.301368. Epub 2013 Oct 17.

45. Gray R.W., Wilz D.R., Caldas A.E., Lemann J. Jr. The importance of phosphate in regulating plasma 1,25-(OH)2-vitamin D levels in humans: Studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1977;45:299–306.

46. Caldas A.E., Gray R.W., Lemann, J., Jr. The simultaneous measurement of vitamin D metabolites in plasma: Studies in healthy adults and in patients with calcium nephrolithiasis. J. Lab. Clin. Med. 1978;91:840.

47. Dzeranov N.K., Lopatkin N.A. Urinary stone disease. The clinical guidelines. M., «Overlei», 2007. P. 224–249. Russain (Дзеранов Н.К., Лопаткин Н.А. Мочекаменная болезнь. Клинические рекомендации. М., «Оверлей», 2007. С. 224–249).

48. Pytel’ A.Y., Lopatkin N.A. Urologiia. M.: Medicina. 1970. p. 289. Russian (Пытель А.Я., Лопаткин Н.А. Урология. М., «Медицина». 1970.С. 289).

49. Taylor E.N., Hoofnagle A.N., Curhan G.C. Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones. Clin J Am Soc Nephrol. 2015;10(4):667–675. doi: 10.2215/CJN.07060714.

50. Wang H., Man L., Li G., Huang G., Liu N. Association between serum vitamin D levels and the risk of kidney stone: evidence from a meta-analysis. Nutrition Journal 2016 doi.org/10.1186/s12937-016-0148-y.

51. Bogosyan A.B., Shlyakova E.Y., Karataeva D.S., Musikhina I.V., Puchenkina E.V.Disorders of phosphorus-calcium metabolism in children with pathology of the musculoskeletal system. Medical Almanac. 2011;6 (19):213–216 Russian (Богосьян А.Б., Шлякова Е.Ю., Каратаева Д.С., Мусихина И.В., Пученкина Е.В. Нарушения фосфорно-кальциевого метаболизма у детей при патологии опорно-двигательного аппарата. Медицинский Альманах. 2011;6(19):213–216).

52. Verbovoy A.F., Sharonova L.A., Kapishnikov V.A., Demidov D. V. Vitamin D3, osteoprotegerin and other hormonal and metabolic parameters in women with diabetes type 2 diabetes. Obesity and metabolism. 2012;4: 23–27. Russian (Вербовой А.Ф., Шаронова Л.А., Капишников А.В., Демидова Д.В. Витамин D3, остеопротегерин и другие гормонально-метаболические показатели у женщин с сахарным диабетом 2 типа. Ожирение и метаболизм. 2012;4:23–27).

53. Drygina L.B., Dorofeychik-Drygina N.A., Prohoroca O.V. The status of Vitamin D during development of osteodeficit in firefighters of Russian Ministry of Emergency Situations. Medico-biological and socio-psychological problems of safety in emergency situations. 2013;3:5–9. Russian (Дрыгина Л.Б., Дорофейчик-Дрыгина Н.А., Прохорова О.В. Статус витамина D при формировании остеодефицита у пожарных МЧС России. Медико-биологические и социально-психологические проблемы безопасности в чрезвычайных ситуациях. 2013;3:5–9).

54. Rozhinskaya L.Ya., Pigarova E.A., Dzeranova L.K., Sen’ko O.V., Kuznetsova A.V., Cherepanova E.A., Melnichenko G.A. Identifying the «cut-off» point of suppression of excessive PTH secretion: method of finding the point of correlation change. Osteoporosis International. 2014;25(suppl. 2):280.

55. Cashman K.D., Dowling K.G., Skrabakova Z., Gonzales-Gross M. Vitamin D deficiency in Europe: pandemic? Fm J Clin Nutr. 2016;103:1033–1044.

56. Hollis B.W., Wagner C.L. Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. Am J Clin Nutr. 2004;80(6 Suppl):1752S–8S.

57. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.; Chen TC. Photobiology of vitamin D. In: Holick MF, ed. Vitamin D physiology, molecular biology, and clinical applications. Clifton, NJ: Humana Press, 1998:17–37.

58. Sneve M., Figenschau Y., Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. European Journal of Endocrinology/European Federation of Endocrine Societies. 2008;159(6):675–684.

59. British Nutrition Foundation and The British Dietetic Association Ltd. 2016. Р. 3–6.

60. Pipili C., Oreopoulos D.G. Vitamin D status in patients with recurrent kidney stones. Nephron Clin Pract. 2012;122(3–4):134–38. Doi: 10.1159/000351377.

61. Eisner B.H., Thavaseelan S., Sheth S., Haleblian G., Pareek G. Relationship between serum vitamin D and 24-hour urine calcium in patients with nephrolithiasisUrology. 2012;80(5):1007–10. Doi: 10.1016/j.urology.2012.04.041. Epub 2012 Jun 13.

62. Aloia J.F., Patel M., Dimaano R., Li-Ng M., Talwar S.A., Mikhail M., Pollack S.,Yeh J.K. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008;87(6):1952–1958. PubMed PMID: 18541590.

63. Penniston K.L., Jones A.N., Nakada S.Y., Hansen K.E. Vitamin D repletion does not alter urinary calcium excretion in healthy postmenopausal women. BJU international. 2009;104(10):1512–1516. Doi:10.1111/j.1464-410X.2009.08559.x.

64. Johri N., Jaeger Ph., Ferraro P.M., Shavit L., Nair D., Robertson W.G., Gambaro G., Unwin R.J. Vitamin D deficiency is prevalent among idiopathic stone formers, but does correction pose any risk? Urolithiasis. 2017;45(6):535–543.

65. Dalbeth N. et al. The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. Rheumatology (Oxford). 2009;48:195–197.

66. Bobulescu I.A., Moe O.W. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19:358–371.

67. Ferraro P.M., Taylor E.N., Gambaro G., Curhan G.C. Vitamin D Intake and the Risk of Incident Kidney Stones. J Urol. 2017;197(2):405–410. Doi:10.1016/j.juro.2016.08.084.

68. Leaf D.E., Korets R., Taylor E.N., Tang J., Asplin J.R., Goldfarb D.S., Gupta M.,Curhan G.C. Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers. Clin J Am Soc Nephrol. 2012;7(5):829–834.

69. Ferroni M.C., Rycyna K.J., Averch T.D., Semins M.J. Vitamin D Repletion in Kidney Stone Formers: A Randomized Controlled Trial. J Urol. 2017;197(4):1079–1083.

70. Blair D., Byham-Gray L., Lewis E., McCaffrey S. Prevalence of vitamin D

71. Taylor E.N., Stampfer M.J., Curhan G.C. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol JASN 2004;15(12):3225–3232.

72. Nguyen S., Baggerly L., French C., Heaney R.P., Gorham E.D., Garland C.F. 25-Hydroxyvitamin D in the range of 20 to 100 ng/mL and incidence of kidney stones. Am J Public Health 2014;104(9):1783–1787.

73. Avenell A., Mak J.C., O’Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev 2014;4:CD000227.

74. Bjelakovic G., Gluud L.L., Nikolova D., Whitfield K., Wetterslev J., Rg S., Bjelakovic M., Gluud C. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2014;1: CD007470.

75. Bjelakovic G., Gluud L.L., Nikolova D., Whitfield K., Krstic G.,Wetterslev J.,Gluud C. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev 2014;6:CD007469.

76. Malihi Z., Wu Zh., Stewart A.W, Lawes C.M., Scragg R. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr. 2016;104(4):1039–1051. Doi: 10.3945/ajcn.116.134981 (2016).

77. Kearns M.D., Alvarez J.A., Tangpricha V. Large, single-dose, oral vitamin d supplementation in adult populations: a systematic review. Endocr Pract. 2014;20:341–351.

78. Ferroni M.C., Rycyna K.J., Averch T.D., Semins M.J. Vitamin D Repletion in Kidney Stone Formers: A Randomized Controlled Trial. J Urol. 2017;197(4):1079–1083. Doi: 10.1016/j.juro.2016.10.057.

79. Autier P., Boniol M., Pizot C. et al. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2:76–89.

80. Zerwekh J.E., Sakhaee K., Glass K., Pak C.Y. Long term 25-hydroxyvitamin D3 therapy in postmenopausal osteoporosis: demonstration of responsive and nonresponsive subgroups. J Clin Endocrinol Metab. 1983;56:410–413.

81. Haghighi A, Samimagham H., Gohardehi G. Calcium and vitamin D supplementation and risk of kidney stone formation in postmenopausal women. Iran J Kidney Dis. 2013;7(3):210–223.

82. Domrongkitchaiporn S., Ongphiphadhanakul B., Stitchantrakul W., Piaseu N., Chansirikam S., Puavilai G., Rajatanavin R. Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women. Osteoporos Int. 2000;11(6):486–492.

83. Jackson R.D., LaCroix A.Z., Gass M. et al. Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669–683.

84. Letavernier E., Verrier C., Goussard F., Perez J., Huguet L., Haymann J-P, Baud L., Bazin D., Daudon M. Calcium and vitamin D have a synergistic role in a rat model of kidney stone disease. Kidney Int J Kint. 2016.05.027

85. Parks J.H., Worcester E.M., Coe F.L. et al. Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int. 2004;66:777–785.